Logo image of AMRN

AMARIN CORP PLC -ADR (AMRN) Stock Fundamental Analysis

NASDAQ:AMRN - Nasdaq - US0231114044 - ADR - Currency: USD

15.65  +0.61 (+4.06%)

After market: 15.66 +0.01 (+0.06%)

Fundamental Rating

3

Taking everything into account, AMRN scores 3 out of 10 in our fundamental rating. AMRN was compared to 550 industry peers in the Biotechnology industry. AMRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, AMRN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AMRN had negative earnings in the past year.
In the past year AMRN has reported a negative cash flow from operations.
In the past 5 years AMRN reported 4 times negative net income.
In the past 5 years AMRN reported 4 times negative operating cash flow.
AMRN Yearly Net Income VS EBIT VS OCF VS FCFAMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

AMRN has a Return On Assets of -15.46%. This is amongst the best in the industry. AMRN outperforms 81.09% of its industry peers.
AMRN has a better Return On Equity (-22.28%) than 82.91% of its industry peers.
Industry RankSector Rank
ROA -15.46%
ROE -22.28%
ROIC N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
AMRN Yearly ROA, ROE, ROICAMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

Looking at the Gross Margin, with a value of 54.10%, AMRN is in the better half of the industry, outperforming 77.45% of the companies in the same industry.
AMRN's Gross Margin has declined in the last couple of years.
AMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
AMRN Yearly Profit, Operating, Gross MarginsAMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AMRN has been increased compared to 1 year ago.
Compared to 5 years ago, AMRN has more shares outstanding
AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMRN Yearly Shares OutstandingAMRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AMRN Yearly Total Debt VS Total AssetsAMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

AMRN has an Altman-Z score of -1.81. This is a bad value and indicates that AMRN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.81, AMRN is in line with its industry, outperforming 54.36% of the companies in the same industry.
There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.81
ROIC/WACCN/A
WACC7.49%
AMRN Yearly LT Debt VS Equity VS FCFAMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.26 indicates that AMRN has no problem at all paying its short term obligations.
AMRN's Current ratio of 3.26 is on the low side compared to the rest of the industry. AMRN is outperformed by 61.09% of its industry peers.
AMRN has a Quick Ratio of 2.34. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
AMRN's Quick ratio of 2.34 is on the low side compared to the rest of the industry. AMRN is outperformed by 69.45% of its industry peers.
Industry RankSector Rank
Current Ratio 3.26
Quick Ratio 2.34
AMRN Yearly Current Assets VS Current LiabilitesAMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AMRN have decreased strongly by -33.75% in the last year.
Looking at the last year, AMRN shows a very negative growth in Revenue. The Revenue has decreased by -17.17% in the last year.
The Revenue for AMRN have been decreasing by -11.86% on average. This is quite bad
EPS 1Y (TTM)-33.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1071.43%
Revenue 1Y (TTM)-17.17%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%7.78%

3.2 Future

AMRN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.76% yearly.
Based on estimates for the next years, AMRN will show a very strong growth in Revenue. The Revenue will grow by 26.83% on average per year.
EPS Next Y-4.16%
EPS Next 2Y19.64%
EPS Next 3Y16.46%
EPS Next 5Y17.76%
Revenue Next Year-11.1%
Revenue Next 2Y-8.29%
Revenue Next 3Y-3.57%
Revenue Next 5Y26.83%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AMRN Yearly Revenue VS EstimatesAMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AMRN Yearly EPS VS EstimatesAMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMRN Price Earnings VS Forward Price EarningsAMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMRN Per share dataAMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

A more expensive valuation may be justified as AMRN's earnings are expected to grow with 16.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.64%
EPS Next 3Y16.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMRN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMARIN CORP PLC -ADR

NASDAQ:AMRN (8/15/2025, 8:05:14 PM)

After market: 15.66 +0.01 (+0.06%)

15.65

+0.61 (+4.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)10-28 2025-10-28
Inst Owners17.64%
Inst Owner Change-15.81%
Ins Owners0.77%
Ins Owner Change0.61%
Market Cap324.06M
Analysts42.5
Price Target16.32 (4.28%)
Short Float %2.02%
Short Ratio3.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)151.18%
Min EPS beat(2)-30.72%
Max EPS beat(2)333.07%
EPS beat(4)2
Avg EPS beat(4)82.39%
Min EPS beat(4)-30.72%
Max EPS beat(4)333.07%
EPS beat(8)5
Avg EPS beat(8)65.32%
EPS beat(12)7
Avg EPS beat(12)55.23%
EPS beat(16)9
Avg EPS beat(16)35.66%
Revenue beat(2)1
Avg Revenue beat(2)6.91%
Min Revenue beat(2)-18.83%
Max Revenue beat(2)32.65%
Revenue beat(4)2
Avg Revenue beat(4)19.27%
Min Revenue beat(4)-18.83%
Max Revenue beat(4)70.07%
Revenue beat(8)5
Avg Revenue beat(8)16.14%
Revenue beat(12)8
Avg Revenue beat(12)11.62%
Revenue beat(16)9
Avg Revenue beat(16)6.62%
PT rev (1m)18.52%
PT rev (3m)18.52%
EPS NQ rev (1m)0.45%
EPS NQ rev (3m)7.92%
EPS NY rev (1m)0%
EPS NY rev (3m)27.29%
Revenue NQ rev (1m)2.59%
Revenue NQ rev (3m)-8.93%
Revenue NY rev (1m)0.75%
Revenue NY rev (3m)-3.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.48
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-2.14
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS10.59
BVpS22.45
TBVpS21.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.46%
ROE -22.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.1%
FCFM N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.26
Quick Ratio 2.34
Altman-Z -1.81
F-Score3
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1071.43%
EPS Next Y-4.16%
EPS Next 2Y19.64%
EPS Next 3Y16.46%
EPS Next 5Y17.76%
Revenue 1Y (TTM)-17.17%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%7.78%
Revenue Next Year-11.1%
Revenue Next 2Y-8.29%
Revenue Next 3Y-3.57%
Revenue Next 5Y26.83%
EBIT growth 1Y-90.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.04%
EBIT Next 3Y18.17%
EBIT Next 5YN/A
FCF growth 1Y32.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.99%
OCF growth 3YN/A
OCF growth 5YN/A